Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OK Biotech CoTPE:4155 -2.03%75 EV-to-EBIT is 8.34 as of Aug. 25, 2026, which is 55% below its 10-year median of 18.47. GuruFocus rates TPE:4155 with a GF Score™ of 75/100 and a GF Value™ of NT$19.89 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 476 Medical Devices & Instruments companies, OK Biotech Co ranks better than 80.04% on this metric.
The historical rank and industry rank for OK Biotech Co's EV-to-EBIT or its related term are showing as below:
TPE:4155'
s EV-to-EBIT Range Over the Past 10 Years
Min: -244.86 Med: 18.47 Max: 214.15
Current: 8.34
During the past 13 years, the highest EV-to-EBIT of OK Biotech Co was 214.15. The lowest was -244.86. And the median was 18.47.
TPE:4155's EV-to-EBIT is ranked better than 80.04% of 476
companies
in the Medical Devices & Instruments industry
Industry Median: 19
vs TPE:4155: 8.34
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
OK Biotech Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$2,782 Mil.
OK Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$303 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OK Biotech Co EV-to-EBIT Related Terms
OK Biotech Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for OK Biotech Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, OK Biotech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OK Biotech Co EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OK Biotech Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where OK Biotech Co's EV-to-EBIT falls into.
OK Biotech Co's current Enterprise Value is NT$2,527 Mil.
OK Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$303 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OK Biotech Co (TPE:4155) has a EV-to-EBIT of 8.34 as of Aug. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on OK Biotech Co and its competitors. This is 55% below median its historical median of 18.47. According to the industry distribution chart, OK Biotech Co ranks #95 out of 476 companies in the Medical Devices & Instruments industry, placing it in the top 20%.
Is OK Biotech Co's EV-to-EBIT too high?
OK Biotech Co's current EV-to-EBIT of 8.34 is 55% below median its 10-year median of 18.47. The Medical Devices & Instruments industry median EV-to-EBIT is 19.00. OK Biotech Co's value of 8.34 is 56.1% below this industry median. Based on the distribution chart, OK Biotech Co ranks #95 out of 476 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, OK Biotech Co has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does OK Biotech Co's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, OK Biotech Co ranks #95 out of 476 companies for EV-to-EBIT. This places OK Biotech Co in the top 20% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 19.00. OK Biotech Co's value of 8.34 is 56.1% below this benchmark. While the company's 10-year median is 18.47 vs. the industry median of 19.00, OK Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.00, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OK Biotech Co's current EV-to-EBIT of 8.34 is 56.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on OK Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OK Biotech Co's current EV-to-EBIT is 8.34, which is 55% below median its own 10-year median of 18.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OK Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, OK Biotech Co (TPE:4155) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$19.89, compared to a current price of NT$14.45 — trading 27.4% below its estimated fair value. The current EV-to-EBIT is 8.34, which is 55% below median its 10-year median of 18.47 and 56.1% below the Medical Devices & Instruments industry median of 19.00. OK Biotech Co's overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For OK Biotech Co (TPE:4155), the current EV-to-EBIT is 8.34 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OK Biotech Co (TPE:4155) Overvalued in 2026?
Based on GuruFocus' analysis, OK Biotech Co stock appears to be undervalued.
The current stock price of NT$14.45 is trading 27.4% below its estimated GF Value™ of NT$19.89.
GuruFocus considers OK Biotech Co to be Modestly Undervalued.
Key valuation signals for TPE:4155:
EV-to-EBIT: 8.34 (55% below median its 10-year median of 18.47)
GF Value™: NT$19.89 vs. price of NT$14.45 (27.4% below fair value)
Industry Position: 56.1% below the Medical Devices & Instruments median (#95 of 476)
No single metric tells the full story. See the TPE:4155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OK Biotech Co Ltd is mainly engaged in the manufacturing, wholesale, and retail of electronic materials and medical equipment. Its product portfolio comprises blood glucose monitoring systems, OTC hearing aids, multi-frequency therapy devices, and others. Geographically, the company generates the majority of its revenue from America, and the rest from Asia (excluding Taiwan), Africa, Europe, and Taiwan.
75GF Score
Get the complete analysis for TPE:4155
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4155 has been successfully added to your 
